Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity

被引:11
作者
Bowman, BJ [1 ]
Ofner, CM [1 ]
机构
[1] Univ Sci Philadelphia, Philadelphia Coll Pharm, Dept Pharmaceut Sci, Philadelphia, PA 19104 USA
关键词
gelatin methotrexate conjugates; protein conjugation; protein conjugate stability; hydrolytic release from protein conjugates; site-specific conjugation; crosslinking; conjugate fragments;
D O I
10.1023/A:1026460023503
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. Our laboratory has previously prepared gelatin/ methotrexate (MTX) conjugates containing mixed conjugation sites and by-product crosslinking, both of which may alter conjugate effectiveness. In this study, we prepared and evaluated gelatin/MTX conjugates having specific conjugate bond sites and minimal byproduct crosslinking. Methods. Opposite polarity conjugates were produced by coupling gelatin having blocked amino groups with MTX (G-MTX) and by coupling MTX having blocked amino groups with gelatin (M-GEL) using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl. Amino groups were blocked using citraconic anhydride and deblocked under acidic conditions. Gelatin and MTX contents were determined spectrophotometrically. The stability of each conjugate was determined by evaluating their in vitro release of MTX in isotonic buffer at pH 7.4 and 37 degreesC for 7 days. Results. The G-MTX and M-GEL conjugates contained 21 and 1.2 mole MTX/mole gelatin and released 12 and 17% MTX by 7 days resulting in pseudo-first order release rate constants of 0.76x10(-3) and 1.0x10(-3) hr(-1), respectively. Alternate MTX species (less than or equal to 10%) were detected during the release study and were attributed to low molecular weight gelatin/MTX fragments and MTX polymers. Conclusions. Gelatin/MTX conjugates having opposite conjugate bond polarities and minimal by-product crosslinking have been produced and slowly released MTX by hydrolytic cleavage indicating good stability for future cell culture studies.
引用
收藏
页码:1309 / 1315
页数:7
相关论文
共 31 条
[1]  
Allegra C J, 1990, Cancer Chemother Biol Response Modif, V11, P1
[2]   Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate [J].
Boratynski, J ;
Opolski, A ;
Wietrzyk, J ;
Górski, A ;
Radzikowski, C .
CANCER LETTERS, 2000, 148 (02) :189-195
[3]  
BOWMAN B, 1998, PHARMSCI, V1, pS581
[4]  
BURES L, 1990, NEOPLASMA, V37, P225
[5]  
CHEN C, 1999, PHARMSCI, V1, pS481
[6]  
Coopman PJ, 1998, CLIN CANCER RES, V4, P507
[7]  
FITZPATRICK JJ, 1995, ANTI-CANCER DRUG DES, V10, P11
[8]  
Ghosh M K, 1989, Drug Des Deliv, V4, P13
[9]   CHARACTERIZATION OF INVITRO DRUG RELEASE AND BIOLOGICAL-ACTIVITY OF METHOTREXATE-BOVINE SERUM-ALBUMIN CONJUGATES [J].
HALBERT, GW ;
FLORENCE, AT ;
STUART, JFB .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1987, 39 (11) :871-876
[10]   INFLUENCE OF CARRIER ON BIODISTRIBUTION AND INVITRO CYTOTOXICITY OF METHOTREXATE BRANCHED POLYPEPTIDE CONJUGATES [J].
HUDECZ, F ;
CLEGG, JA ;
KAJTAR, J ;
EMBLETON, MJ ;
PIMM, MV ;
SZEKERKE, M ;
BALDWIN, RW .
BIOCONJUGATE CHEMISTRY, 1993, 4 (01) :25-33